Диссертация (1335905), страница 26
Текст из файла (страница 26)
– 2013. –Vol.37, №3. – P. 239-48.65.Dusso, A.S. Pathogenic mechanisms for parathyroid hyperplasia / A.S. Dusso,T. Sato, M.V. Arcidiacono, D. Alvarez-Hernandez, J. Yang, I. GonzalezSuarez, Y. Tominaga, E. Slatopolsky // Kidney Int. – 2006. – Vol.70 (Suppl102). – P. 8-11.15166.Foley, R.N. The fall and rise of parathyroidectomy in U.S.
hemodialysispatients, 1992 to 2002./ R.N. Foley, S. Li, J. Liu, D.T. Gilbertson, S.C. Chen,A.J. Collins // J Am Soc Nephrol. – 2005. – Vol.16, №1. – P. 210-8.67.Fukagawa, M. Selective percutaneous ethanol injection therapy (PEIT) of theparathyroid in chronic dialysis patients: the Japanese strategy / M. Fukagawa,M. Kitaoka, Y. Tominaga, T. Akizawa, K. Kurokawa // Nephrol DialTransplant. – 1999. – Vol.14. – P. 2574-7.68.Giammanco, M. Vitamin D in cancer chemoprevention / M. Giammanco, D. DiMajo, M. La Guardia, S.
Aiello, M. Crescimannno, C. Flandina, F.M.Tumminello // Leto G.Pharm Biol. – 2015. – Vol.53, №10. – P. 1399-434.69.Giangrande, A. Ultrasonically guided fine-needle alcohol injection as anadjunct to medical treatment in secondary hyperparathyroidism / GiangrandeA., Cantù P., Solbiati L., Ravetto C. // Proc Eur Dial Transplant Assoc Eur RenAssoc. – 1985. – Vol.21. – P. 895-90170.Goldsmith, D.
Should patients with CKD stage 5D and biochemical evidence ofsecondary hyperparathyroidism be prescribed calcimimetic therapy? An ERAEDTA position statement / D. Goldsmith, A. Covic, M. Vervloet, M.Cozzolino, I. Nistor // Nephrol Dial Transplant. – 2015. – Vol.30, №5. – P. 698700.71.Goodman, W.G. Coronary-artery calcification in young adults with end-stagerenal disease who are undergoing dialysis / W.G. Goodman, J. Goldin, B.D.Kuizon, C. Yoon, B. Gales, D. Sider, Y. Wang, J. Chung, A.
Emerick, L.Greaser, R.M. Elashoff, I.B. Salusky // N Engl J Med. - 2000. – Vol.342, №20.– P. 1478-83.72.Hansen, D. The influence of vitamin D analogs on calcification modulators, Nterminal pro-B-type natriuretic peptide and inflammatory markers inhemodialysis patients: a randomized crossover study / D.
Hansen, K.Rasmussen, L.M. Rasmussen, H. Bruunsgaard, L. Brandi // BMC Nephrol. –2014. – Vol.15. – P. 130.15273.Hedgeman, E. International burden of chronic kidney disease and secondaryhyperparathyroidism: a systematic review of the literature and available data.
/E. Hedgeman, L. Lipworth, K. Lowe, R. Saran, T. Do, J. Fryzek // Int JNephrol. – 2015. – 184321.74.Heng, A-E. Nutritional problems in adult patients with stage 5 chronic kidneydisease on dialysis (both haemodialysis and peritoneal dialysis) / A-E. Heng, N.Cano // NDT Plus. – 2010. – Vol.3. – P. 109–117.75.Hirata, M. In subtotally nephrectomized rats 22-oxacalcitriol suppressesparathyroid hormone with less risk of cardiovascular calcification ordeterioration of residual renal function than 1,25(OH)2 vitamin D3 / M. Hirata,K. Katsumata, K. Endo, N.
Fukushima, H. Ohkawa, M. Fukagawa // NephrolDial Transplant. – 2003. - V.18. - P.1770–1776.76.Hong, Y.A. Diameter of Parathyroid Glands Measured by ComputedTomography as a Predictive Indicator for Response to Cinacalcet in DialysisPatients with Secondary Hyperparathyroidism / Y.A. Hong, Y.S. Cho, S.W.Kim, M.Y. Jung, E.A. Lee, G.J. Ko, H.J. Pyo, S.Y. Hwang, S.
Suh, Y.J. Kwon// Kidney Blood Press Res. – 2015. – Vol.40, №3. – P. 277-87.77.Hruska, K.A. The predictability of the histological features of uremic bonedisease by non-invasive techniques / KA Hruska, SL Teiltelbaum, R. Kopelman// Metab Bone Dis Rel Res. – 1978. – №1. – P. 39.78.Huang, C.Y.
Effects of pamidronate and calcitriol on the set point of theparathyroid gland in postmenopausal hemodialysis patients with secondaryhyperparathyroidism / C.Y. Huang, C.M. Zheng, C.C. Wu, L. Lo, K.C. Lu, P.Chu // Nephron Clin Pract. – 2012. – Vol.122, №3-4. – P. 93-101.79.Hutchison, A.J . Improving phosphate-binder therapy as a way forward / A.J.Hutchison // Nephrol Dial Transplant. – 2004. – Vol.19 Suppl 1 – P. 19-24.80.Hutchison, A.J.
Lanthanum carbonate treatment, for up to 6 years, is notassociated with adverse effects on the liver in patients with chronic kidneydisease Stage 5 receiving hemodialysis / A.J. Hutchison, M.E. Barnett, R.Krause, G.A. Siami // Clin Nephrol. – 2009. – Vol.71. – P.286–295.15381.Imai, E. Prevalence of chronic kidney disease (CKD) in the Japanese generalpopulation predicted by the MDRD equation modified by a Japanese coefficient/ E. Imai, M. Horio, K. Iseki, K.
Yamagata, T. Watanabe, S. Hara, N. Ura, Y.Kiyohara, H. Hirakata, T. Moriyama, Y. Ando, K. Nitta, D. Inaguma, I. Narita,H. Iso, K. Wakai, Y. Yasuda, Y. Tsukamoto, S. Ito, H. Makino, A. Hishida, S.Matsuo // Clin Exp Nephrol. - 2007. – Vol.11, №2. – P. 156-63.82.Isakova, T. Phosphorus binders and survival on hemodialysis / T. Isakova,O.M. Gutiérrez, Y. Chang, A.
Shah, H. Tamez, K. Smith, R. Thadhani, M.Wolf // J Am Soc Nephrol. – 2009. – Vol.20, №2. – P. 388-96.83.Ishani, A. Clinical outcomes after parathyroidectomy in a nationwide cohort ofpatients on hemodialysis / A. Ishani, J. Liu, J.B. Wetmore, K.A. Lowe, T. Do,B.D. Bradbury, G.A. Block, A.J. Collins // Clin. J. Am.
Soc. Nephrol. – 2015. –Vol.10, №1 – P. 90-7.84.Ishimura, E. Serum magnesium concentration is a significant predictor ofmortality in maintenance hemodialysis patients / E. Ishimura, S. Okuno, T.Yamakawa, M. Inaba, Y. Nishizawa // Magnes Res. - 2007. – Vol.20, №4. – P.237-44.85.Iwamoto, N. Total parathyroidectomy improves survival of hemodialysispatients with secondary hyperparathyroidism / N Iwamoto, N Sato, M Nishida,T Hashimoto, H Kobayashi, S Yamasaki, T Ono, M Nishimura, T Tokoro, CSakoda, M Murakawa, K Okino, Y Okamoto, R Imai, N Adachi, K Ninomiya,H Mabuchi, M Koyama, T Nakanouchi, K. Iseki // J. Nephrol. – 2012. –Vol.25, №5. – P.
755-63.86.Jamal S.A. The effects of calcium-based versus non-calcium-based phosphatebinders on mortality among patients with chronic kidney disease: a metaanalysis / S.A. Jamal, D. Fitchett, C.E. Lok, D.C. Mendelssohn, R.T. Tsuyuki //Nephrol Dial Transplant. – 2009. – Vol.24, №10. – P. 3168-74.87.Jamal, S.A.
Effect of calcium-based versus non-calcium-based phosphatebinders on mortality in patients with chronic kidney disease: an updatedsystematic review and meta-analysis / S.A. Jamal, B. Vandermeer, P. Raggi,154D.C. Mendelssohn, T. Chatterley, M. Dorgan, C.E. Lok, D. Fitchett, R.T.Tsuyuki // Lancet.
– 2013. - Vol.382, №9900. – P. 1268-77.88.Jiang, Z. Effect of restricted protein diet supplemented with keto analogues inchronic kidney disease: a systematic review and meta-analysis / Z. Jiang, X.Zhang, L. Yang, Z. Li, W. Qin // Int Urol Nephrol. – 2016. – Vol.48, №3. –409-18.89.Kalantar-Zadeh, K. Survival predictability of time-varying indicators of bonedisease in maintenance hemodialysis patients / K. Kalantar-Zadeh, N. Kuwae,D.L.
Regidor, C.P. Kovesdy, R.D. Kilpatrick, C.S. Shinaberger, C.J.McAllister, M.J. Budoff, I.B. Salusky, J.D. Kopple // Kidney Int. – 2006. –Vol.70, №4. – P. 771–780.90.Karamanidou, C. A systematic review of the prevalence and determinants ofnonadherence to phosphate binding medication in patients with end-stage renaldisease / C. Karamanidou, J. Clatworthy, J. Weinman, R. Horne // BMCNephrol. – 2008 – №9.
– P. 2.91.Ketteler, M. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy forthe treatment of secondary hyperparathyroidism in patients receivinghaemodialysis: results of the IMPACT SHPT study/ M. Ketteler, K.J. Martin,M. Wolf, M. Amdahl, M. Cozzolino, D. Goldsmith, A. Sharma, S. Marx, S.Khan // Nephrol Dial Transplant. – 2012. – Vol. 27, №8. – P.
3270-8.92.Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD WorkGroup. KDIGO clinical practice guideline for the diagnosis, evaluation,prevention, and treatment of Chronic Kidney Disease-Mineral and BoneDisorder (CKD-MBD). // Kidney Int Suppl. 2009. – Vol.113. – P. 1-130.93.Kim, S.M. Rates and Outcomes of Parathyroidectomy for SecondaryHyperparathyroidism in the United States / S.M. Kim, J.
Long, M.E. MontezRath, M.B. Leonard, J.A. Norton, G.M. Chertow // Clin J Am Soc Nephrol. 2016. – Vol.11, №7. –P.1260-7.94.Koiwa, F. Efficacy of percutaneous ethanol injection therapy (PEIT) is relatedto the number of parathyroid glands in hemodialysis patients with secondary155hyperparathyroidism / F. Koiwa, T. Kakuta, R. Tanaka, S. Yumita // Nephrol.Dial.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
